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Purpose: Sorafenib is the only approved drug in ﬁrst-line treatment for hepatocellular
carcinoma. Recently, the Phase III REFLECT trial proved lenvatinib not inferior to sorafenib,
potentially establishing a new standard of care in this setting. The study showed that both
have similar overall survivals, yet with longer time to progression for lenvatinib. Currently,
the selection of one or other is not based on clinical or biological parameters for this reason
we performed a network meta-analysis and we also analyzed the REFLECT trial and its
implications in the current and future clinical practice.
Materials and methods: We performed the meta-analysis according to the Prisma state-
ment recommendations. HR was the measure of association for time to progression and
overall survival. The pooled analysis of HR was performed using a random effect model,
ﬁxing a 5% error as index of statistical signiﬁcance.
Results: For HBV-positive patients, there was a clear trend in favor of lenvatinib over
sorafenib (HR 0.82 95% credible interval [CrI] 0.60–1.15). For HCV-positive no differences
between lenvatinib and sorafenib were observed (HR 0.91 95% CrI 0.41–2.01). The data
showed that lenvatinib could be the best drug for HBV-positive patients in 59% of cases
compared to only 1% of patients treated with sorafenib.
Conclusion: The identiﬁcation of clinical or biological markers that could predict response
or resistance to treatments is needed to guide treatment decision. This network meta-analysis
demonstrates that the etiology is a good candidate and this result should be validated in
a speciﬁc trial.
Keywords: sorafenib, hepatocellular carcinoma, randomized trial, biomarkers, erlotinib,
linifanib, sunitinib, brivanib
Introduction
Sorafenib was approved thank to two positive trials, the SHARP study in 20071 and
the Asia Paciﬁc study in 2008.2 However, clinical trials investigating sunitinib,3
brivanib,4 and linifanib5 as ﬁrst-line treatments, with sorafenib as a control arm,
failed to meet their primary endpoint of improving overall survival (OS). Sorafenib
is the only systemic drug approved in this setting of patients. Lenvatinib represents
an alternative molecular-targeted therapy option for hepatocellular carcinoma
(HCC) patients.6 It is an oral multireceptor tyrosine kinase inhibitor (TKI) of the
activities of the vascular endothelial growth factor (VEGF) receptors (VEGFR1,
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VEGFR2, and VEGFR3), the ﬁbroblast growth factor
(FGF) receptors (FGFR1, FGFR2, FGFR3, and FGFR4)
and the alpha and beta platelet-derived growth factor
receptors.7–10
The VEGF-signaling pathway is the key regulator of
tumor growth and metastasis;11 VEGFR2 induces major
phenotypic changes of endothelial cells in angiogenesis,
including proliferation, migration, survival, and tube
formation.12
The most important difference between this drug and
other TKIs, especially sorafenib, is the ability to potently
inhibit FGFRs. The FGFR signaling pathway plays an
important role in diverse cell functions, including prolif-
eration, differentiation, apoptosis, and migration, and also
in tumor proliferation, angiogenesis, migration, and
survival.13-15FGFR pathway could be subject to various
somatic aberrations, such as gene ampliﬁcation, point
mutations, translocations, and isoform switching, resulting
in carcinogenesis.16,17In vivo, lenvatinib shows a more
potent anti-tumor activity than in vitro.18,19
Preliminary evidence20 of tumor shrinkage in HCC
patients resulted in the design of a single-arm, open-
label, multicenter Phase II trial21 evaluating lenvatinib in
patients with advanced HCC. In this trial, 46 patients were
enrolled at 14 sites across Japan and Korea to receive
lenvatinib. As for the primary endpoint, a median TTP of
7.4 months (95% CI 5.5–9.4) was obtained. The study
showed a 37% ORR and a stable disease in 41% of
patients with a 78% disease control rate (mRECIST cri-
teria). Median OS was 18.7 months (95% CI 12.7–25.1).
Following the results of the Phase II trial,
a randomized, open-label Phase III trial was designed6
with the aim to determine whether lenvatinib was not
inferior to sorafenib in advanced HCC in term of OS.
The non-inferiority margin was set at 1.08. A total of 954
patients were randomly assigned to receive either lenva-
tinib (n=478) or sorafenib (n=476). A median OS of 13.6
months (95% CI 12.1–14.9) and 12.3 months (95%
CI 10.4–13.9) was reached in the lenvatinib arm and the
sorafenib arm, respectively, with a HR)of 0.92 (95%
CI 0.79–1.06), thus meeting the criteria for non-
inferiority. The secondary endpoint of progression-free
survival (PFS) of 7.4 months (95% CI 6.9–8.8) and 3.7
months (95% CI 3.6–4.6) was in favor of the lenvatinib
arm (HR 0.66 P<0.0001). Similarly, the lenvatinib arm
showed better ORR than the sorafenib arm (mRECIST
criteria), with ORR of 24.1% (20.2–27.9) and 9.2%
(6.6–11.8), respectively (OR 3.13 P<0.0001).
The lenvatinib arm and the sorafenib arm showed
different toxicity proﬁles. The most common any-grade
advserse events (AEs) for lenvatinib were hypertension
(42%), diarrhea (39%), decreased appetite (34%), and
decreased weight (13%), whereas palmar-plantar erythro-
dysesthesia (52%), diarrhea (46%), hypertension (30%),
and decreased appetite (27%) for sorafenib. Treatment-
related grade ≥3 AEs were observed in 57% and 49% of
patients in the lenvatinib arm and in the sorafenib arm,
respectively. Similarly, serious treatment-related AEs were
more frequent in the lenvatinib arm with an incidence of
18% vs 10% in the sorafenib arm.
Actually the indication of Lenvatinib and Sorafenib are
in ﬁrst line in patients with advanced hepatocellular carci-
noma. Currently, the selection of one or other is not based
on clinical or biological parameters.
To date, there are no validated prognostic nor predic-
tive markers of response to sorafenib in HCC, although
hepatitis status seems to be a potential candidate.
In the subgroup analysis of the SHARP study1, sor-
afenib showed an advantage in term of OS on subgroup
of patients positive for HCV (0.50; 95% CI 0.32-0.77),
differently no different was observed in HBV-positive
patients (0.76; 95% CI 0.38–1.50, P=not signiﬁcant).
The same results were obtained for TTP (HR =1.03
and 0.43 for HBV-positive and HCV-positive patients,
respectively). These data were conﬁrmed in the Asia-
Paciﬁc trial. In the pooled analysis of the SHARP and
Asia- Paciﬁc trials, Bruix et al conﬁrmed that the
absence of HCV was a potential prognostic factor for
poorer OS (HR 0.7, P=0.02). The authors revealed that
HBV-positive patients did not show a signiﬁcant differ-
ence in treatment response compared to HBV-negative
patients (HR =0.78; 95% CI 0.57–1.06) and OS (HR
=1.128, P=0.4538).
A recent meta-analysis by Jackson et al22 highlighted
that the beneﬁt in OS depends on the patient’s status of
hepatitis. OS improves in HBV-negative and HCV-positive
patients when treated with sorafenib. However, as recently
pointed out by Personeni et al,23 Jackson et al only con-
sidered negative data from randomized trials comparing
sorafenib with other drugs (brivanib,4 linifanib5, and
sunitinib3), disregarding both the SHARP1 and the Asia-
Paciﬁc2 trials that evaluated sorafenib against placebo. For
this reason, we performed a meta-analysis of these two
randomized studies and a network meta-analysis (NMA)
between sorafenib and lenvatinib, assessing the different
outcomes related to the different etiologies.
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Materials and methods
Meta-analysis of SHARP trial and
Asia-Paciﬁc study
Study design and inclusion criteria
Clinical trials comparing sorafenib and placebo were
searched in PubMed. Only randomized controlled trials
(sorafenib vs placebo) that included patients with hepato-
cellular carcinoma were considered eligible and included
in the quantitative analysis.
Figure 1 reports the search strategy followed in this
meta-analysis. A bibliographic research was conducted of
the PubMed, EMBASE, Cochrane Library, and Embase
databases. Keyword used included ‘‘sorafenib and hepato-
cellular carcinoma and randomized trial and placebo.”
Data extraction and management
Two review authors (ACG and ET) independently
screened the titles and abstracts of all the selected studies.
All the abstracts of potentially eligible trials were inde-
pendently read by the same authors that decided if the
study was selected. The full text of all selected papers
was then analyzed by the same authors to select all the
trials ﬁnally included in the pooled analysis. When dis-
crepancies in trial search or selection occurred, they were
discussed with a third researcher (GLF) to reach a ﬁnal
consensus. The quality of the studies included in this meta-
analysis was assessed using the Cochrane risk of bias tool.
The risk of bias in this meta-analysis was low.
Statistical analysis
We performed the meta-analysis according to the Prisma
statement recommendations.10 Data were entered in
a computer database for transfer and statistical analysis
in Review Manager 5.2. Heterogeneity among the trials
was assessed with descriptive aim using the I2 test. Any
level <5% was considered as statistically signiﬁcant. HR
was the measure of association for time to progression
(TTP) and OS. The pooled analysis of HR was performed
using a random effect model, ﬁxing a 5% error as index of
statistical signiﬁcance.
NMA of virus etiology
The model for the NMA was ﬁt as previously
suggested.24 Data were extracted from the publications
or estimated as proposed by Parmar et al.25 Treatment
effects were estimated by posterior means and 95%
credible intervals (CrIs) using random effect, identity
link function, and non-informative prior distributions
(uniform and normal). We performed 25,000 iterations
with burn-in number of 5,000 iterations and a thin inter-
val of 20 to obtain the posterior distributions of model
parameters. Convergence was assessed using the
Brooks–Gelman–Rubin method. Posterior distributions
were used to assess the probability of each treatment to
be the best, second best, and so on. Inconsistency and
heterogeneity were assessed using node-split models, I2,
and Cochran Q tests. Signiﬁcant heterogeneity was con-
sidered to be present for I2>50% or p-value >0.10. Der
Simonian and Laird method and random effect were
used. All the analyses were made with the R packages
“Metaphor” and “Gemtc” (https://www.r-project.org/).
The quality of the studies included in this meta-
analysis was assessed using the Cochrane risk of bias
tool. The risk of bias in this meta-analysis was low.
Results
Meta-analysis of SHARP trial and
Asia-Paciﬁc study
Two studies1,2 were analyzed for this present work. They
included 120 and 138 HCC patients treated with sorafenib,
and 96 and 87 with placebo for HCV and HBV analysis,
respectively. Both studies are sub-analyses of a Phase III
trial. The two studies were considered of high quality with
low risk of bias.
The results of the meta-analysis showed a signiﬁcant ben-
eﬁt of sorafenib for HCV-positive patients in terms of TTP
(HR 0.39 CI 95% 0.25–0.62 P<0.0001) and OS (HR 0.52
CI 95% 0.36–0.76 P=0.0006) (Figure 1A and Figure 1B).
HBV-positive patients showed a trend in favor of sorafenib
rather than placebo for TTP (HR 0.74 CI 95% 0.48–1.14
p = 0.18) and OS (HR 0.74 CI 95% 0.544-1.03 p = 0.08)
(Figure 1C and Figure 1D). No heterogeneity was detected
for the outcomes.
NMA of virus etiology
The NMAwas performed on a total of 1,788 patients on six
study,1–26 of these 1160 patients were HCV-positive or
HBV-positive. Of these, 251 (21.6%) HBV-positive patients
and 91 (7.8%) HCV-positive patients received lenvatinib,
whereas 390 (33.6%) HBV-positive patients and 229
(19.7%) HCV-positive patients received sorafenib. A total
of 114 (9.8%) HBV-positive patients and 85 (7.3%)
HCV-positive patients received placebo. All studies were
considered of high quality with low risk of bias.
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In the overall population no difference was observed
between lenvatinib and sorafenib, despite if a slight trend
toward a greater efﬁcacy of lenvatinib (HR 0.92, 95% CrI
0.61–1.36) (Figure 2A). Both lenvatinib and sorafenib
were signiﬁcantly better than placebo.
When we restricted the analysis to HBV-positive patients,
a signiﬁcant beneﬁt in terms of OSwas estimated for sorafenib
(HR 0.78 95% CrI 0.62–0.97) with respect to placebo; for
HBV-positive patients there was a clear trend in favor of
lenvatinib over sorafenib (HR 0.82 95% CrI 0.60–1.15)
(Figure 2B).
For HCV-positive no differences between lenvatinib and
sorafenib were observed (HR 0.91 95% CrI 0.41–2.01)
(Figure 2C). I2, Cochran's Q, and node-split models showed
no evidence of heterogeneity nor inconsistency, strengthen-
ing the results of the NMA.
The rankogram in Figure 3 reports the probably best
approach for these patients. The rankogram shows that
Lenvatinib was probably the best approach for HBV-
positive patients.
Discussion
Lenvatinib has a biological rationale for use in patients
with advanced HCC. The REFLECT study was well
designed, despite being open-label.6
What is key to our study is whether a non-inferiority
study can change clinical practice. Table 1 lists the most
important factors that may inﬂuence this choice of
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Figure 1 Result of the meta-analysis; time to progression (A) and overall survival (B) for hepatitis C-positive patients; time to progression (C) and overall survival (D) for
hepatitis B-positive patients.
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treatment. The ﬁrst is the toxicity proﬁle compared to the
standard of care. Lenvatinib showed a non-negligible
safety proﬁle, proving no advantage against sorafenib:
patients in the sorafenib arm had more dermatological
AEs, but less hypertension than patients in the lenvatinib
arm. Generally, dermatological AEs carry no risk of death,
although they often compromise the patient’s quality of
life (QoL), and can be resolved by dose decrease or treat-
ment interruption. Patients receiving lenvatinib had
a better QoL, as also demonstrated by a sub-analysis of
the REFLECT study. However, hypertension can be rarely
associated with serious complications regardless of treat-
ment interruption. The second factor is the cost of the new
drug compared to the standard of care: a lower price with
similar efﬁcacy and toxicity proﬁle can well inﬂuence the
doctor’s decision in clinical practice. Finally, patients who
tolerate sorafenib may undergo regorafenib for disease
progression as an effective second-line alternative,
whereas no results are available about any effective option
for disease progression beyond lenvatinib.
In the context, the identiﬁcation of biomarkers or clin-
ical parameters that could predict response or resistance to
treatments is needed to guide treatment decision.
Our data from NMA highlighted that lenvatinib has
a greater activity in HBV-positive patients. The data showed
that lenvatinib could be the best drug for HBV-positive
patients in 59% of cases compared to only 1% of patients
treated with sorafenib.
This is a crucial point because actually we could have
clinical parameters to select better the best treatment for
Brivanib
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Figure 2 Results of Network Meta Analysis in all population (A); hepatitis B-positive patients (B) and hepatitis C-positive patients (C).
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the patients. Our ﬁndings seem to conﬁrm previous sug-
gestions on this topic although further conﬁrmatory data
may be necessary.
We believe that future prospective studies should aim
to customize therapy based on the etiology. For example,
a sub-analysis of the RESOURCE study27 highlights, as
we have already pointed out,28 that the HR for OS was
0.58 (95% CI 0.41–0.82 P=0.0009) in HBV-positive
patients against 0.79 (95% CI 0.49-1.26 P=0.1583) in
HCV-positive patients. Similar data were observed for
PFS (0.39 vs 0.59, respectively) and TTP (0.38 vs 0.57,
respectively). Actually, we have more drug in advanced
hepatocellular in the same line. Future study must be
aimed to identify a best strategy in ﬁrst and second line.
Conclusion
In conclusion, the identiﬁcation of clinical or biological
markers that could predict response or resistance to treat-
ments is needed to guide treatment decision. This NMA
demonstrates that the etiology is a good candidate and this
result should be validated in a speciﬁc trial.
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